

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**上海醫藥集團股份有限公司**  
**Shanghai Pharmaceuticals Holding Co., Ltd.\***

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 02607)**

**2022 THIRD QUARTERLY REPORT**

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The following is the third quarterly report for 2022 of Shanghai Pharmaceuticals Holding Co., Ltd.. The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By order of the Board  
**Shanghai Pharmaceuticals Holding Co., Ltd.\***  
**ZHOU Jun**  
*Chairman*

Shanghai, the PRC, 28 October 2022

*As at the date of this announcement, the executive directors of the Company are Mr. CHO Man, Mr. LI Yongzhong and Mr. SHEN Bo; the non-executive directors are Mr. ZHOU Jun, Mr. GE Dawei and Ms. LI An; and the independent non-executive directors are Mr. CAI Jiangnan, Mr. HONG Liang, Mr. GU Zhaoyang and Mr. Manson FOK.*

\* *For identification purpose only*

The board of directors of the Company and all directors warrant that there are no false representations or misleading statements or material omissions contained in this announcement, and assume legal liabilities for the truthfulness, accuracy and completeness thereof.

## **IMPORTANT NOTICE**

The board of directors, the board of supervisors and the directors, supervisors of the Company and senior management hereby warrant that the contents contained in this quarterly report is true, accurate and complete and contain no false representations, misleading statements or material omissions and assume joint and several legal liabilities therefor.

Zhou Jun, the person in charge of the Company, Cho Man, the principal in charge of accounting, and Shen Bo, head of the accounting department (chief financial officer), hereby declare that they warrant the truthfulness, accuracy and completeness of the financial information contained in this quarterly report.

Whether the third quarterly financial statements were audited

Yes  No

## **DEFINITIONS**

In this report, unless the context otherwise requires, all the relevant financial data has been prepared in accordance with the requirements of the PRC Accounting Standards, and the following terms shall have the following meanings:

“Shanghai Pharmaceuticals”, “the Group”, “Group”, the “Company” or “Company”	Shanghai Pharmaceuticals Holding Co., Ltd.* (上海醫藥集團股份有限公司), a joint stock company incorporated in the PRC with limited liability (the Shares of which are listed on the Shanghai Stock Exchange with stock code 601607, and on the Main Board of the Hong Kong Stock Exchange with stock code 02607) or Shanghai Pharmaceuticals Holding Co., Ltd.* and its subsidiaries, where applicable
“YOY”	year-on-year
“the PRC” or “China”	the People’s Republic of China, unless the context otherwise requires, references to the PRC or China in this report do not include Hong Kong, Macau and Taiwan
“Shares”	shares of Shanghai Pharmaceuticals with a nominal value of RMB1.00 each, comprising both A Shares and H Shares
“A Shares”	domestic shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Shanghai Stock Exchange and traded in RMB

“H Shares”	overseas shares of the Company, with a nominal value of RMB1.00 each, which are listed on the Hong Kong Stock Exchange and traded in Hong Kong dollars
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“Hong Kong Stock Exchange”	The Stock Exchange of Hong Kong Limited
“SIIC”	Shanghai Industrial Investment (Holdings) Co., Ltd. (上海實業(集團)有限公司)
“Shanghai Shangshi”	Shanghai Shangshi (Group) Co., Ltd. (上海上實(集團)有限公司)
“Shanghai Pharmaceutical (Group)”	Shanghai Pharmaceutical (Group) Co., Ltd. (上海醫藥(集團)有限公司)
“Yunnan Baiyao”	Yunnan Baiyao Group Co., Ltd. (雲南白藥集團股份有限公司)
“Guosheng Group”	Shanghai Guosheng (Group) Co., Ltd. (上海國盛(集團)有限公司) and its wholly-owned subsidiary Shanghai Shengrui Investment Co., Ltd. (上海盛睿投資有限公司), Shanghai Guosheng Group Assets Co., Ltd. (上海國盛集團資產有限公司)
“Abbott Pharmaceutical”	Shanghai Abbott Pharmaceutical Co., Ltd (上海雅培製藥有限公司)
“Luoxin Pharmaceutical”	Luoxin Pharmaceutical Group Stock Co., Ltd. (羅欣藥業集團股份有限公司)
“Luye Pharma”	Luye Pharma Group Ltd.
“SHAPHAR”	Shanghai Pharmaceutical Co., Ltd. (上藥控股有限公司)
“CanSino SPH”	CanSino SPH Biologics Inc. (48.958% owned by Shanghai Pharmaceuticals, 1.245% owned by Shanghai Biomedical Industrial Equity Investment Fund and 49.797% owned by CanSino Biologics Inc. respectively)
“SPH Cloud Health”	Shanghai Pharmaceuticals Grand Health Cloud Commerce Company Limited (上海醫藥大健康雲商股份有限公司)
“MediTrust Health”	Shanghai MediTrust Health Co., Ltd. (上海鎂信健康科技有限公司)

## I. MANAGEMENT DISCUSSION AND ANALYSIS

### Results overview

From January to September 2022, the main business of the Company continued to grow fast. The operating income of the Company amounted to RMB174.612 billion, representing a YOY increase of 8.47%. Of which, the sales revenue from the pharmaceutical manufacturing was RMB19.793 billion, representing a YOY increase of 5.35% and the sales revenue from the pharmaceutical services was RMB154.819 billion, representing a YOY increase of 8.89%. From July to September 2022, the operating income of the Company amounted to RMB62.904 billion, representing a YOY increase of 12.86%. Of which, the sales revenue from the pharmaceutical manufacturing was RMB6.743 billion, representing a YOY increase of 9.02%; the sales revenue from the pharmaceutical services was RMB56.161 billion, representing a YOY increase of 13.34%.

From January to September 2022, the Company recorded RMB4.814 billion of net profit attributable to equity holders of the listed company, representing a YOY increase of 7.35%. The profit of the main business of the pharmaceutical manufacturing and the pharmaceutical services continued to maintain a healthy growth. Of which, the pharmaceutical manufacturing contributed profits of RMB1,652 million, representing a YOY increase of 4.01%, the pharmaceutical services contributed profits of RMB2,413 million, representing a YOY increase of 15.94% and major shareholding enterprises contributed profits of RMB478 million, representing a YOY decrease of 32.40%. The Company recorded RMB3.698 billion of net profit after deduction of non-recurring profit or loss attributable to equity holders of the listed company, representing a YOY increase of 4.31%. After deducting the investment income of shareholding enterprises, the net profit after deduction of non-recurring profit or loss attributable to shareholders of the parent company for the first three quarters increased by 14.11% YOY. From July to September 2022, the net profit attributable to equity holders of the listed company amounted to RMB1.118 billion, representing a YOY increase of 22.02%.

From January to September 2022, the R&D investment of the Company achieved RMB1,692 million, representing a YOY decrease of 1.34%. Of which, the expensed R&D investment amounted to RMB1.389 billion, representing a YOY increase of 1.63%. From July to September 2022 the expensed R&D investment for the current quarter amounted to RMB579 million, representing a YOY increase of 19.05%.

### Pharmaceutical manufacturing

From January to September 2022, the Company's sales revenue from pharmaceutical manufacturing was RMB19.793 billion, increasing by 5.35% compared with the same period of last year, and the gross profit margin was 58.05%, increasing by 0.49 percentage point compared with the same period of last year. On the list of Shanghai Top 100 Enterprises in 2022, Shanghai Pharmaceuticals ranked 12th in "Shanghai Top 100 Enterprises in 2022" and 4th in "Top 100 Manufacturing Enterprises in Shanghai", and continued to maintain its leading position.

**As a large pharmaceutical industry group facing the world, Shanghai Pharmaceuticals is driven by scientific and technological innovation, actively expanding cooperation with universities and institutions, and realizing original innovation in the true sense through platform and industry incubation.** Hong Kong has the innate location advantage of developing biomedical science and technology innovation industry. Shanghai Pharmaceuticals promotes the interconnection between Shanghai and Hong Kong from three aspects of R&D linkage, industrial linkage and capital linkage, promotes R&D innovation, builds a new industry pillar of Shanghai and Hong Kong, and seeks coordinated development. During the Reporting Period, Shanghai Pharmaceuticals also discussed the possibility of project cooperation and various cooperation modes with universities and research centers in Hong Kong, etc.

**Up to now, the Company's clinical application has been accepted and 53 new drug pipelines have entered the clinical research stage, including 43 innovative drugs and 10 improved new drugs. Among the innovative drug pipelines, 8 innovative drug pipelines are in the key research, clinical phase III and follow-up research stages.** During the Reporting Period, the Company's R&D projects achieved the following phased results:

- The new anti-tumor project B013 injection has obtained the Notice of Approval for Drug Clinical Trial approved and issued by the National Medical Products Administration, and the phase II clinical trial of triple-negative breast cancer indications will be started in the near future;
- The new autoimmunity drug project I001-B has obtained the Notice of Approval for Drug Clinical Trial approved and issued by the National Medical Products Administration, and the phase II clinical trial of ulcerative colitis will be started in the near future;
- The new acute stroke drug I037 was approved for phase II clinical trial;
- All the patients in the phase II clinical trial of I008-A project were out of the group, and a pre-NDA/conditional marketing communication application was submitted for T8 AIDS indications.

From July to September 2022, 2 new varieties (2 specifications) of Shanghai Pharmaceuticals passed the consistency evaluation of generic drugs, which increased the number of products approved for consistency evaluation to 46 varieties (68 specifications), ranking first in the industry.

**Continuously promoting the cultivation of large varieties of traditional Chinese medicine is a strategic measure of the traditional Chinese medicine industry sector of Shanghai Pharmaceuticals.** In August 2022, Tianjin University of Traditional Chinese Medicine-Shanghai Pharmaceuticals Joint Research Institute held a seminar on the cultivation of large varieties of traditional Chinese medicine. Academician Zhang Boli, the expert team of Tianjin University of Traditional Chinese Medicine and Shanghai Pharmaceuticals fully discussed the progress and follow-up work direction of related cooperation projects of key varieties of Shanghai Pharmaceuticals, such as Yuxuebi capsule, Trichosanthes Peel injection, anti-aging tablets and Babaodan, and communicated with each other on the research and development needs of key varieties such as Yangxinshi, Ginkgo biloba ester and Shenxiang Suhe pill, and exchanged views on measures to promote the cultivation of large varieties of traditional Chinese medicine, and the brand value cultivation, research directions and technical paths of related varieties.

**The Company actively carries out the layout in the vaccine field.** At present, CanSino SPH has a full set of GMP production capacity from stock solution production to preparation filling. It is the only super-large viral vector drug production base in the Yangtze River Delta, and it also has a technology development service platform and an animal experiment service platform. In the selection of the fourth government quality award in Baoshan District, CanSino SPH won the “Quality Innovation Award” for its high starting point planning and high standard quality management mode. In September this year, CanSino SPH became one of the first batch of “innovative vaccine chain leading enterprises” in Shanghai Innovative Vaccine Science and Technology Park. In the same month, the recombinant COVID-19 vaccine for inhalation (adenovirus type 5 vector) (trade name: Convidecia Air) was put into emergency use as booster. If the inhalation vaccine is further popularized and used, it will be helpful to the business development of CanSino SPH.

### **Pharmaceutical service**

From January to September 2022, sales revenue from the pharmaceutical distribution business of the Company was RMB155.198 billion, representing a YOY increase of 9.33%, and the gross profit margin was 6.28%. The sales revenue from the pharmaceutical retail business was RMB5.680 billion, representing a YOY increase of 0.76%, and the gross profit margin thereof was 11.74%.

**The Company strives to build an innovative drug service platform, providing one-stop management services of the whole supply chain covering four major areas of pre-marketing cooperation, import and export services, nationwide distribution and innovation and value-added for innovative products of pharmaceutical enterprises around the world.** In September 2022, SHAPHAR signed strategic cooperation agreements with Abbott Laboratories, Luye Pharma and Luoxin Pharmaceuticals, respectively, by virtue of the rich management experience and efficient import supply chain service advantages of innovative drug whole life cycle service platform. The Company's perfect distribution and retail network throughout the country can also quickly realize the marketing of drugs and better serve strategic partners. Up to now in 2022, the Company has added a total of 23 new imported products under general agency, and continues to maintain the leading position of the general commercial agent of imported innovative drugs.

The Company actively lays out the **“Internet+” pharmaceutical commercial technology platform. SPH Cloud Health** has built the integrated brand of “Yiyao”, and is committed to developing the innovative link among pharmaceutical companies, hospitals and patients by taking out-of-hospital market of innovative drugs as the core and construction of the professional pharmaceutical service capability as the cornerstone. SPH Cloud Health has now established the leading whole cycle service platform for innovative drug commercialization in China, thereby providing the domestic booming innovative drug industry with a full range of commercial solutions covering clinical research and development phase of innovative drugs and the out-of-hospital drug market after marketing. Based on this, SPH Cloud Health continues to deepen its digital business and upgrade its Internet platform so as to provide professional services such as digital marketing, patient service, innovative payment, and Internet hospital operation of public hospitals for the government and medical institutions, R&D and pharmaceutical enterprises as well as payers.

**MediTrust Health** is deeply involved in the City Customized Commercial Medical Insurance in different parts of the country, and has promoted the new mode that people who are already sick can be insured and acquire indemnities, which has benefited nearly 100 million people in total, covering 21 provinces, municipalities and autonomous regions, and more than 100 cities. Among them, after the launching of the first provincial-level project “Huiminbao” (惠閩寶) Insurance with MediTrust Health as the comprehensive service operator, there were nearly 200,000 people joining insurance within 8 hours. In the “Huiminbao” (惠閩寶) Insurance project, MediTrust Health not only provided claim settlement service for special drugs, but also participated in various links such as the design of drug guarantee catalogue, medical insurance claims service, value-added service and operation and promotion. With the launch of “Huiminbao” (惠閩寶) Insurance products, the role of MediTrust Health in urban insurance projects has been switched from special drug service supporter to the comprehensive service operator.

## II. MAJOR FINANCIAL DATA

### Major accounting data and financial indicators

Unit: Yuan Currency: RMB

Items	Reporting Period	Increase/decrease of the Reporting Period as compared to the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Increase/decrease of the period from the beginning of the year to the end of the Reporting Period as compared to the corresponding period of last year (%)
Operating revenue	62,904,454,549.86	12.86	174,611,918,877.50	8.47
Net profit attributable to equity holders of the listed company	1,118,299,638.36	22.02	4,813,906,174.07	7.35
Net profit after deduction of non-recurring profit or loss attributable to equity holders of listed company	1,016,848,300.08	2.32	3,697,637,549.65	4.31
Net cash flows from operating activities	397,427,280.62	-47.26	-158,753,779.87	-105.43
Basic earnings per Share (RMB per share)	0.30	-0.06	1.45	-8.01
Diluted earnings per Share (RMB per share)	0.30	-0.06	1.45	-8.01
Weighted average return on net assets (%)	1.70	Decreased by 0.20 percentage point	8.29	Decreased by 1.21 percentage points

	As at the end of the Reporting Period	As at the end of last year	Increase/decrease as at the end of the Reporting Period as compared with the end of last year (%)
Total assets	194,617,751,423.18	163,435,509,161.71	19.08
Owners' equity attributable to equity holders of the listed company	66,174,932,666.15	49,359,479,911.36	34.07

Note: the "Reporting Period" represents the 3-month period from the beginning of this quarter to the end of this quarter, the same below.



## Non-recurring profit or loss items and amounts

Unit: Yuan Currency: RMB

Items	Amount for the Reporting Period	Amount from the beginning of the year to the end of the Reporting Period
Profit or loss on disposal of non-current assets	-10,712,735.41	1,412,177,639.42
Government grants recognised in profit or loss for the current period excluding those closely related to the Company's ordinary operations and granted on an ongoing basis under the national policies according to certain fixed quota of amount or volume	92,880,329.34	216,920,147.24
Except for the effective hedging activities related to the Company's ordinary operations, profit or loss arising from changes in fair value of financial assets held for trading, derivative financial assets, financial liabilities held for trading, and derivative financial liabilities, and investment income from disposal of financial assets held for trading, derivative financial assets, financial liabilities held for trading, derivative financial liabilities and other debt investments	48,144,245.07	73,535,591.16
Reversal of provisions on impairment for receivables and contract assets assessed for impairment on an individual basis	5,901,851.06	22,869,182.99
Other non-operating income and expenses other than the aforesaid items	-12,195,999.91	-53,437,603.27
Less: Effect on income tax	-10,208,786.98	-243,678,780.69
Effect on minority interests (after tax)	-12,357,564.89	-312,117,552.43
Total	101,451,338.28	1,116,268,624.42

Explanation on the fact that the non-recurring profit or loss items illustrated in the Explanatory Announcement on Information Disclosure for Companies Offering Their Securities to the Public No. 1 – Non-recurring Profit or Losses were defined as its recurring profit or loss items

Applicable  Not applicable

## Changes in major accounting data and financial indicators and the reasons thereof

Applicable     Not applicable

Items	Change (%)	Main reason
Owners' equity attributable to equity holders of the listed company – as at the end of the Reporting Period	34.07	Increase in non-public issuance of shares from the beginning of the year to the end of the Reporting Period
Net cash flows from operating activities – from the beginning of the year to the end of the Reporting Period	-105.43	The slow-down collection of payment for goods with the impact of the pandemic from the beginning of the year to the end of the Reporting Period
Net cash flows from operating activities – during the Reporting Period	-47.26	The slow-down collection of payment for goods with the impact of the pandemic during the Reporting Period

### III. INFORMATION ON SHAREHOLDERS<sup>①</sup>

Total number of shareholders of ordinary Shares and shareholders of preference Shares with restored voting rights and shareholdings of the top ten shareholders

*Unit: share*

Total number of shareholders of ordinary Shares as at the end of the Reporting Period <sup>②</sup>	113,835	Total number of shareholders of preference Shares with voting right restored as at the end of the Reporting Period (if any)	0			
<b>Shareholdings of the top ten shareholders</b>						
Name of shareholders	Nature of shareholders	Number of Shares held	Shareholding percentage (%)	Number of trade-restricted Shares held	Pledged, labelled or frozen	
					Status	Number
Shanghai Pharmaceutical (Group)	State-owned legal person	716,516,039	19.384	0	Nil	
HKSCC NOMINEES LIMITED <sup>③</sup>	Foreign legal person	710,146,524	19.212	0	Unknown	
Yunnan Baiyao	Domestic non-state-owned person	665,626,796	18.007	665,626,796	Nil	
SHC and its wholly-owned subsidiaries and Shanghai Shangshi and its wholly-owned subsidiaries <sup>④</sup>	State-owned legal person	593,800,498	16.064	187,000,000	Nil	
China Securities Finance Corporation Limited	Unknown	59,319,243	1.605	0	Nil	
Hong Kong Securities Clearing Company Limited <sup>⑤</sup>	Foreign legal person	57,933,139	1.567	0	Unknown	
Guosheng Group	State-owned legal person	44,632,100	1.207	0	Nil	
China Merchants Bank Co., Ltd. – Industrial Income Enhancement Bond Securities Investment Fund	Unknown	16,170,148	0.437	0	Unknown	
Bank of Ningbo Co., Ltd. – Zhongtai Xingyuan Value Selected Flexible Allocation Mixed Securities Investment Fund	Unknown	14,671,225	0.397	0	Unknown	
Yinhua Fund – Agricultural Bank – Yinhua China Securities and Financial Assets Management Program	Unknown	11,708,022	0.317	0	Unknown	

Shareholdings of top ten shareholders without trade restrictions			
Name of shareholders	Number of Shares in circulation without trade restrictions	Class and number of Shares	
		Class	Number
Shanghai Pharmaceutical (Group)	716,516,039	RMB ordinary Shares	716,516,039
HKSCC NOMINEES LIMITED	710,146,524	Overseas listed foreign Shares	710,146,524
SIIC and its wholly-owned subsidiaries and Shanghai Shangshi	406,800,498	RMB ordinary Shares	222,301,798
		Overseas listed foreign Shares	184,498,700
China Securities Finance Corporation Limited	59,319,243	RMB ordinary Shares	59,319,243
Hong Kong Securities Clearing Company Limited	57,933,139	RMB ordinary Shares	57,933,139
Guosheng Group	44,632,100	RMB ordinary Shares	21,117,000
		Overseas listed foreign Shares	23,515,100
China Merchants Bank Co., Ltd. – Industrial Income Enhancement Bond Securities Investment Fund	16,170,148	RMB ordinary Shares	16,170,148
Bank of Ningbo Co., Ltd. – Zhongtai Xingyuan Value Selected Flexible Allocation Mixed Securities Investment Fund	14,671,225	RMB ordinary Shares	14,671,225
Yinhua Fund – Agricultural Bank – Yinhua China Securities and Financial Assets Management Program	11,708,022	RMB ordinary Shares	11,708,022
Harvest Fund – Agricultural Bank – Harvest China Securities and Financial Assets Management Program	9,986,887	RMB ordinary Shares	9,986,887
Note on connected relations or concerted actions of the above shareholders	SIIC is the de facto controller of Shanghai Shangshi, which is a controlling shareholder of Shanghai Pharmaceutical (Group). Shanghai Guosheng (Group) Co. Ltd. is a wholly-owned subsidiary of Shanghai SASAC. Shanghai Shengrui Investment Co., Ltd. and Shanghai Guosheng Group Assets Co., Ltd. are wholly-owned subsidiaries of Shanghai Guosheng (Group) Co. Ltd.. The Company is not aware of any affiliation among other shareholders or whether they are persons acting in concert as stipulated under the “Administrative Measures for the Acquisition of Listed Companies”.		
Note on the top ten shareholders and top ten shareholders without trade restrictions who participated in margin financing and securities lending and refinancing business (if any)	/		

- ① As at the end of the Reporting Period, the total issued Shares of the Company amounted to 3,696,414,318, comprising 2,777,341,614 A Shares and 919,072,704 H Shares;
- ② Among the 113,835 shareholders as at the end of the Reporting Period, 112,053 were A shareholders and 1,782 were H shareholders;
- ③ Shares held by HKSCC NOMINEES LIMITED are held on behalf of its clients and the number of Shares it holds as shown in the table above excludes the 184,498,700 H Shares held and controlled by SIIC and its wholly-owned subsidiaries and 23,515,100 H Shares held and controlled by Guosheng Group through Southbound Trading;
- ④ The 187,000,000 A Shares held by Shanghai Tandong Enterprise Consulting Services Co., Ltd. were included in the number of Shares held by Shanghai Shangshi and its wholly-owned subsidiaries;
- ⑤ Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary Shares under Shanghai-Hong Kong Stock Connect.

## **VI. OTHER REMINDERS**

Other important information in relation to the operation of the Company during the Reporting Period that needs to be brought to the attention of the investors

Applicable  Not applicable

## **V. QUARTERLY FINANCIAL STATEMENTS**

### **(I) Type of audit opinion**

Applicable  Not applicable

**(II) Financial Statements****CONSOLIDATED BALANCE SHEET**

30 September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan Currency: RMB Type of Audit: Unaudited*

<b>Items</b>	<b>30 September 2022</b>	<b>31 December 2021</b>
<b>Current assets:</b>		
Monetary funds	25,491,177,416.72	22,390,385,718.86
Deposit reservation for balance		
Lending funds		
Financial assets held for trading	12,582,637,222.22	–
Derivative financial assets	6,463,266.83	3,284,464.66
Notes receivable	1,178,656,681.89	1,278,880,689.20
Accounts receivable	72,254,428,236.65	58,107,770,169.75
Receivables financing	1,437,651,409.75	1,619,009,831.53
Advances to suppliers	3,081,674,565.97	2,457,761,134.48
Premiums receivable		
Reinsurance accounts receivable		
Receivable from subcontracting reserves		
Other receivables	2,221,948,697.14	2,419,107,971.82
Including: Interests receivable		
Dividends receivable	7,627,773.58	60,179,377.01
Financial assets purchased for resale		
Inventories	28,352,202,885.82	27,104,035,290.12
Contract assets		
Assets classified as held for sale		
Non-current assets due within one year	67,338,390.50	126,505,618.81
Other current asset	800,375,273.40	987,691,443.81
Total current assets	147,474,554,046.89	116,494,432,333.04

Items	30 September 2022	31 December 2021
<b>Non-current assets:</b>		
Issuing of loans and advances		
Debt investments		
Other debt investments		
Long-term receivables	229,321,002.03	197,742,289.76
Long-term equity investments	9,686,277,096.92	9,073,275,353.92
Other equity instrument investments	46,934,542.47	73,392,413.17
Other non-current financial assets	1,337,279,665.92	1,388,900,666.61
Investment properties	205,187,569.46	213,323,262.12
Fixed assets	9,908,047,839.57	10,484,118,204.34
Construction in progress	3,795,972,325.99	2,914,130,007.74
Bearer biological assets	400,128,278.75	402,569,065.33
Oil-and-gas assets		
Right-of-use assets	1,910,194,589.45	1,992,433,702.85
Intangible assets	5,842,215,441.33	6,049,431,213.09
Development disbursement	312,187,070.38	259,227,946.08
Goodwill	11,237,548,562.17	11,238,972,360.76
Long-term prepaid expenses	382,828,297.30	429,117,473.86
Deferred income tax assets	1,412,876,420.53	1,367,544,935.42
Other non-current assets	436,198,674.02	856,897,933.62
Total non-current assets	47,143,197,376.29	46,941,076,828.67
Total assets	194,617,751,423.18	163,435,509,161.71

Items	30 September 2022	31 December 2021
<b>Current liabilities:</b>		
Short-term borrowings	29,313,885,945.92	22,514,574,027.35
Borrowing from the Central Bank		
Borrowing funds		
Financial liabilities held for trading		
Derivative financial liabilities	4,267,469.07	774,097.78
Bills payable	4,770,083,139.73	4,764,748,001.67
Accounts payable	44,452,896,794.37	37,230,666,373.90
Advances from customers		
Contract liabilities	1,193,137,710.14	1,310,920,870.47
Financial assets sold for repurchase		
Absorbing deposit and interbank deposit		
Receivings from vicariously traded securities		
Receivings from vicariously sold securities		
Employee benefits payable	1,202,393,458.17	1,433,028,127.78
Taxes payable	1,017,164,888.20	1,692,660,081.03
Other payables	14,449,875,740.28	13,062,527,812.97
Including: Interests payable		
Dividends payable	206,772,639.78	341,551,604.87
Fees and commissions payable		
Reinsurance accounts payable		
Liabilities classified as held for sale		
Non-current liabilities due within one year	1,827,854,500.45	582,042,566.55
Other current liabilities	9,166,881,719.62	9,232,381,601.62
Total current liabilities	107,398,441,365.95	91,824,323,561.12



Items	30 September 2022	31 December 2021
<b>Non-current liabilities:</b>		
Provision for insurance contracts		
Long-term borrowings	6,613,878,906.77	7,157,751,703.48
Bonds payable		
Including: Preference shares		
Perpetual bonds		
Lease liabilities	1,712,842,854.05	1,434,274,148.94
Long-term payables	300,962,389.53	315,161,494.71
Long-term employee benefits payable	37,554,637.13	39,007,184.36
Accrued liabilities	49,976,624.15	23,243,898.02
Deferred income	459,799,507.37	2,349,080,148.54
Deferred income tax liabilities	1,172,731,235.20	998,768,820.78
Other non-current liabilities	255,821,860.40	227,688,064.66
Total non-current liabilities	10,603,568,014.60	12,544,975,463.49
Total liabilities	118,002,009,380.55	104,369,299,024.61
<b>Owners' equity (or shareholders' equity):</b>		
Paid-up capital (or share capital)	3,696,414,318.00	2,842,089,322.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	29,288,352,397.75	16,070,723,052.49
Less: Treasury shares		
Other comprehensive income	-509,780,553.61	-144,394,206.19
Special reserves		
Surplus reserves	1,992,463,708.39	1,992,463,708.39
General risk provisions		
Undistributed profits	31,707,482,795.62	28,598,598,034.67
Total owners' equity (or shareholders' equity) attributable to the parent company	66,174,932,666.15	49,359,479,911.36
Minority interests	10,440,809,376.48	9,706,730,225.74
Total owners' equity (or shareholders' equity)	76,615,742,042.63	59,066,210,137.10
Total liabilities and owners' equity (or shareholders' equity)	194,617,751,423.18	163,435,509,161.71

Legal representative: ZHOU Jun

The principal in charge of accounting: CHO Man

Head of accounting department: SHEN Bo

## CONSOLIDATED INCOME STATEMENT

January – September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan Currency: RMB Type of Audit: Unaudited*

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>I. Total revenue of operation</b>	174,611,918,877.50	160,972,711,401.28
Including: Operating revenue	174,611,918,877.50	160,972,711,401.28
Interest income		
Earned premium		
Service charges and commission		
<b>II. Total cost of operation</b>	168,953,802,013.58	155,830,104,098.80
Including: Cost of operation	151,934,408,923.81	139,260,797,185.25
Interest payments		
Service charges and commission fee		
Surrender charge fee		
Net payments for insurance claims		
Extraction of insurance obligation net reserves		
Policyholder dividend expenses		
Reinsurance expenses		
Business taxes and surcharges	539,137,645.09	481,921,997.47
Selling expenses	10,337,196,939.27	10,216,238,877.12
Administrative expenses	3,756,574,640.46	3,574,522,919.25
R&D expenses	1,388,890,687.62	1,366,568,696.91
Financial expenses	997,593,177.33	930,054,422.80
Including: Interest expenses	1,228,984,711.55	1,114,658,567.41
Interest income	339,629,724.25	236,851,594.24

<b>Items</b>	<b>The first three quarters of 2022 (January to September)</b>	<b>The first three quarters of 2021 (January to September)</b>
Add: Other income	243,793,310.42	271,471,585.21
Investment income (loss indicated by “-”)	445,242,066.46	1,818,199,182.94
Including: Share of investment income of associates and joint ventures	530,520,279.22	769,311,112.43
Gains from derecognition of financial assets measured at amortised cost	-42,752,531.18	-36,085,181.61
Exchange earnings (loss indicated by “-”)		
Net gains from hedging exposure (loss indicated by “-”)		
Profit arising from changes in fair value (loss indicated by “-”)	73,535,591.16	-176,574,836.07
Impairment loss of credit (loss indicated by “-”)	-252,443,012.76	-289,299,908.83
Impairment loss of assets (loss indicated by “-”)	25,891,617.79	28,508,540.39
Gains on assets disposal (loss indicated by “-”)	1,427,203,357.49	6,390,217.59
<b>III. Operating profit (loss indicated by “-”)</b>	<b>7,621,339,794.48</b>	<b>6,801,302,083.71</b>
Add: Non-operating income	19,603,161.73	79,187,434.51
Less: Non-operating expenses	73,040,764.99	83,911,076.08
<b>IV. Total profit (total loss indicated by “-”)</b>	<b>7,567,902,191.22</b>	<b>6,796,578,442.14</b>
Less: Income tax expenses	1,583,651,841.25	1,432,629,039.58
<b>V. Net profit (net loss indicated by “-”)</b>	<b>5,984,250,349.97</b>	<b>5,363,949,402.56</b>
(1) Classified by continuity of operations		
1. Net profit from continuing operations (net loss indicated by “-”)	5,984,250,349.97	5,363,949,402.56
2. Net profit from discontinued operations (net loss indicated by “-”)		

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
(2) Classified by ownership of the equity		
1. Net profit attributable to equity holders of the parent company (net loss indicated by “-”)	4,813,906,174.07	4,484,231,938.15
2. Minority interests (net loss indicated by “-”)	1,170,344,175.90	879,717,464.41
<b>VI. Other comprehensive income, net of tax</b>	-369,830,973.20	56,697,102.14
(1) Other comprehensive income attributable to owners of the parent company, net of tax	-365,386,347.42	68,996,362.22
1. Other comprehensive income that will not be reclassified to profit or loss	-26,457,870.70	14,279,979.27
(1) Changes in the re-measurement of defined benefit plans		
(2) Other comprehensive income accounted for using equity method, which will not be reclassified to profit or loss		
(3) Changes in fair value of investments in other equity instruments	-26,457,870.70	14,279,979.27
(4) Changes in fair value arising from the enterprise’s credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	-338,928,476.72	54,716,382.95
(1) Other comprehensive income accounted for using equity method, which will be reclassified to profit or loss	-245,950.73	350,925.95
(2) Changes in fair value of other debt investments		

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
(3) Other comprehensive income arising from reclassifying financial assets		
(4) Provision for credit impairment of other debt investments		
(5) Cash flow hedging reserve	-257,615.20	–
(6) Exchange differences on translation of financial statements denominated in foreign currencies	-341,694,551.46	54,550,050.38
(7) Others	3,269,640.67	-184,593.38
(2) Other comprehensive income attributable to minority shareholders, net of tax	-4,444,625.78	-12,299,260.08
<b>VII. Total comprehensive income</b>	5,614,419,376.77	5,420,646,504.70
(1) Total comprehensive income attributable to owners of the parent company	4,448,519,826.65	4,553,228,300.37
(2) Total comprehensive income attributable to minority shareholders	1,165,899,550.12	867,418,204.33
<b>VIII. Earnings per Share:</b>		
(1) Basic earnings per Share (RMB/Share)	1.45	1.58
(2) Diluted earnings per Share (RMB/Share)	1.45	1.58

For business combination involving enterprises under common control during the current period, the net profit realized by the acquiree before the business combination is RMB0 as compared to RMB0 for the last period.

Legal representative: ZHOU Jun

The principal in charge of accounting: CHO Man

Head of accounting department: SHEN Bo

## CONSOLIDATED CASH FLOW STATEMENT

January to September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan    Currency: RMB    Type of Audit: Unaudited*

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>I. Cash flows from operating activities:</b>		
Cash received from sales of goods or rendering of services	183,561,595,056.61	175,432,061,155.66
Net increase in customer deposits and interbank deposit payment		
Net increase in borrowing from the Central Bank		
Net increase in funds borrowed from other financial institutions		
Cash received from the receipt of the original insurance contract premiums		
Net cash received from reinsurance business		
Net increase in deposit of the insured and investment fund		
Interest, fees and commissions in cash		
Net increase in funds borrowed		
Net increase in capital for repurchase business		
Net cash received from customer for acting as securities trading agent		
Refund of taxes received	338,075,731.55	74,855,979.38
Cash received relating to other operating activities	1,875,056,713.18	1,576,027,427.64
Sub-total of cash inflows from operating activities	185,774,727,501.34	177,082,944,562.68
Cash paid for goods and services	163,874,058,197.97	153,902,873,057.79
Net increase in customer loans and advances		

<b>Items</b>	<b>The first three quarters of 2022 (January to September)</b>	<b>The first three quarters of 2021 (January to September)</b>
Net increase in placements with Central Bank and interbank		
Cash paid for claims on original insurance contract		
Net increase in lending funds		
Cash paid for interest, fees and commissions		
Cash paid for policy dividend		
Cash paid to and on behalf of employees	6,110,705,454.98	5,738,947,719.63
Payments of taxes	6,307,375,596.35	5,439,587,116.99
Cash paid relating to other operating activities	9,641,342,031.91	9,076,905,800.67
Sub-total of cash outflows from operating activities	185,933,481,281.21	174,158,313,695.08
Net cash flows from operating activities	-158,753,779.87	2,924,630,867.60
<b>II. Cash flows from investing activities:</b>		
Cash received from disposal of investments	21,444,469,956.33	1,907,476,522.38
Cash received from returns on investments	522,943,813.85	506,272,120.09
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	109,237,955.24	72,388,723.44
Net cash received from disposal of subsidiaries and other business units	3,537,318.44	–
Cash received relating to other investing activities	717,524,768.30	525,272,480.51
Sub-total of cash inflows from investing activities	22,797,713,812.16	3,011,409,846.42
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,954,162,817.73	1,781,777,476.87
Cash paid to acquire investments	33,887,100,000.00	2,545,483,542.97
Net increase in pledged loans		
Net cash paid to acquire subsidiaries and other business units	256,951,038.52	1,010,224,333.57
Cash paid relating to other investing activities	783,870,257.45	1,980,820,170.05

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
Sub-total of cash outflows from investing activities	36,882,084,113.70	7,318,305,523.46
Net cash flows from investing activities	-14,084,370,301.54	-4,306,895,677.04
<b>III. Cash flows from financing activities:</b>		
Cash received from capital contributions	14,002,918,408.10	103,720,000.00
Including: Cash received from capital contributions of minority shareholders of subsidiaries	39,025,019.22	103,720,000.00
Cash received from borrowings	36,174,445,828.50	32,111,675,598.78
Cash received from issue of bonds	14,997,633,333.34	15,994,758,880.37
Cash received relating to other financing activities	647,114,956.85	1,560,059,072.85
Sub-total of cash inflows from financing activities	65,822,112,526.79	49,770,213,552.00
Cash paid for repayments of debts	43,459,962,651.36	43,761,137,785.14
Cash paid for distribution of dividends, profits or interest payment	3,140,373,098.39	2,901,556,177.61
Including: Dividends and profits paid to minority shareholders by subsidiaries	387,278,803.67	566,448,227.44
Cash paid relating to other financing activities	2,066,018,784.92	815,781,873.10
Sub-total of cash outflows from financing activities	48,666,354,534.67	47,478,475,835.85
Net cash flows from financing activities	17,155,757,992.12	2,291,737,716.15
<b>IV. Effect of foreign exchange rate changes on cash and cash equivalents</b>	22,203,304.74	-93,074,467.85
<b>V. Net increase in cash and cash equivalents</b>	2,934,837,215.45	816,398,438.86
Add: Balance of cash and cash equivalents at the beginning of the Reporting Period	20,137,500,219.76	19,576,444,789.85
<b>VI. Balance of cash and cash equivalents at the end of the Reporting Period</b>	23,072,337,435.21	20,392,843,228.71

Legal representative: ZHOU Jun

The principal in charge of accounting: CHO Man

Head of accounting department: SHEN Bo



## BALANCE SHEET OF THE PARENT COMPANY

30 September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan    Currency: RMB    Type of Audit: Unaudited*

Items	30 September 2022	31 December 2021
<b>Current assets:</b>		
Monetary funds	6,867,559,672.92	4,956,241,685.91
Financial assets held for trading	12,582,637,222.22	–
Derivative financial assets		
Notes receivable		
Accounts receivable		
Receivables financing		
Advances to suppliers	12,507,012.40	5,462,462.14
Other receivables	18,325,157,491.66	19,489,191,886.01
Including: Interests receivable		
Dividends receivable	889,172,686.84	763,506,050.23
Inventories		
Contract assets		
Assets classified as held for sale		
Non-current assets due within one year		
Other current asset	10,341,848.50	3,728,979.13
Total current assets	37,798,203,247.70	24,454,625,013.19
<b>Non-current assets:</b>		
Debt investments		
Other debt investments		
Long-term receivables	47,686,584.47	–
Long-term equity investments	27,744,153,154.67	26,939,075,300.25
Other equity instrument investments		
Other non-current financial assets	1,022,816,191.73	1,000,330,863.71
Investment properties		
Fixed assets	93,442,537.74	95,247,382.34
Construction in progress	49,531,923.20	41,134,707.27

<b>Items</b>	<b>30 September 2022</b>	<b>31 December 2021</b>
Bearer biological assets		
Oil-and-gas assets		
Right-of-use assets	54,133,795.07	80,816,751.81
Intangible assets	56,434,316.10	67,951,930.43
Development disbursement	72,703,026.05	75,797,743.15
Goodwill		
Long-term prepaid expenses	6,087,581.52	8,013,318.30
Deferred income tax assets		
Other non-current assets	11,382,349.00	305,634,463.20
Total non-current assets	29,158,371,459.55	28,614,002,460.46
Total assets	66,956,574,707.25	53,068,627,473.65
<b>Current liabilities:</b>		
Short-term borrowings	1,300,779,444.44	1,051,400,832.59
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payable		
Accounts payable	20,166,811.67	43,111,344.29
Advances from customers		
Contract liabilities	19,613,176.26	20,097,189.17
Employee benefits payable	517,196.46	64,292,350.69
Taxes payable	20,369,359.76	2,024,631.71
Other payables	14,909,568,299.08	14,675,113,166.07
Including: Interests payable		
Dividends payable		
Liabilities classified as held for sale		
Non-current liabilities due within one year	921,957,162.53	26,539,361.75
Other current liabilities	9,044,884,012.91	9,077,033,424.66
Total current liabilities	26,237,855,463.11	24,959,612,300.93

Items	30 September 2022	31 December 2021
<b>Non-current liabilities:</b>		
Long-term borrowings	80,060,000.00	1,380,000,000.00
Bonds payable		
Including: Preference shares		
Perpetual bonds		
Lease liabilities	40,602,758.58	60,875,539.35
Long-term payables		
Long-term employee benefits payable		
Accrued liabilities		
Deferred income	37,319,794.50	53,628,980.57
Deferred income tax liabilities	5,859,736.77	5,859,736.77
Other non-current liabilities		
Total non-current liabilities	163,842,289.85	1,500,364,256.69
Total liabilities	26,401,697,752.96	26,459,976,557.62
<b>Owners' equity (or shareholders' equity):</b>		
Paid-up capital (or share capital)	3,696,414,318.00	2,842,089,322.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	32,301,820,803.57	19,094,211,080.76
Less: Treasury shares		
Other comprehensive income	-309,592.97	-146,268.20
Special reserves		
Surplus reserves	1,616,672,906.21	1,616,672,906.21
Undistributed profits	2,940,278,519.48	3,055,823,875.26
Total owners' equity (or shareholders' equity)	40,554,876,954.29	26,608,650,916.03
Total liabilities and owners' equity (or shareholders' equity)	66,956,574,707.25	53,068,627,473.65

Legal representative: ZHOU Jun

The principal in charge of accounting: CHO Man

Head of accounting department: SHEN Bo

## INCOME STATEMENT OF THE PARENT COMPANY

January- September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan Currency: RMB Type of Audit: Unaudited*

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>I. Operating revenue</b>	5,039,500.69	8,795,995.64
Less: Cost of operation	1,177,624.93	930,374.26
Business taxes and surcharges	3,612,179.24	150,233.67
Selling expenses		
Administrative expenses	128,340,873.10	153,070,832.71
R&D expenses	323,183,649.00	293,356,864.85
Financial expenses	90,199,767.74	250,016,857.08
Including: Interest expenses	230,018,726.29	266,969,640.69
Interest income	89,938,380.92	30,509,590.62
Add: Other income	12,496,657.56	6,041,178.75
Investment income (loss indicated by “-”)	1,801,456,578.38	2,076,909,659.11
Including: Share of investment income of associates and joint ventures	105,862,534.30	156,969,463.99
Gains from derecognition of financial assets measured at amortised cost		
Net gains from hedging exposure (loss indicated by “-”)		
Profit arising from changes in fair value (loss indicated by “-”)	162,655,949.97	70,954,045.82
Impairment loss of credit (loss indicated by “-”)	724,052.74	1,173,070.84
Impairment loss of assets (loss indicated by “-”)		
Gains on assets disposal (loss indicated by “-”)	3,575,094.30	17,457.89
<b>II. Operating profit (loss indicated by “-”)</b>	1,439,433,739.63	1,466,366,245.48
Add: Non-operating income	48,669.78	2,841,789.10

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
Less: Non-operating expenses	2,533,751.63	869,678.66
<b>III. Total profit (total loss indicated by “-”)</b>	1,436,948,657.78	1,468,338,355.92
Less: Income tax expenses		
<b>IV. Net profit (net loss indicated by “-”)</b>	1,436,948,657.78	1,468,338,355.92
(1) Net profit from continuing operations (net loss indicated by “-”)	1,436,948,657.78	1,468,338,355.92
(2) Net profit from discontinued operations (net loss indicated by “-”)		
<b>V. Other comprehensive income, net of tax</b>	-163,324.77	233,021.80
(1) Other comprehensive income that will not be reclassified to profit or loss		
1. Changes in the re-measurement of defined benefit plans		
2. Other comprehensive income accounted for using equity method, which will not be reclassified to profit or loss		
3. Changes in fair value of investments in other equity instruments		
4. Changes in fair value arising from the enterprise’s credit risk		
(2) Other comprehensive income that will be reclassified to profit or loss	-163,324.77	233,021.80
1. Other comprehensive income accounted for using equity method, which will be reclassified to profit or loss	-163,324.77	233,021.80
2. Changes in fair value of other debt investments		
3. Other comprehensive income arising from reclassifying financial assets		
4. Provision for credit impairment of other debt investments		

<b>Items</b>	<b>The first three quarters of 2022 (January to September)</b>	<b>The first three quarters of 2021 (January to September)</b>
5. Cash flow hedging reserve		
6. Exchange differences on translation of financial statements denominated in foreign currencies		
7. Others		
<b>VI. Total comprehensive income</b>	1,436,785,333.01	1,468,571,377.72
<b>VII. Earnings per Share:</b>		
(1) Basic earnings per Share (RMB/Share)	N/A	N/A
(2) Diluted earnings per Share (RMB/Share)	N/A	N/A

Legal representative: ZHOU Jun                      The principal in charge of accounting: CHO Man  
Head of accounting department: SHEN Bo

## CASH FLOW STATEMENT OF THE PARENT COMPANY

January to September 2022

Prepared by: Shanghai Pharmaceuticals Holding Co., Ltd.\*

*Unit: Yuan    Currency: RMB    Type of Audit: Unaudited*

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>I. Cash flows from operating activities:</b>		
Cash received from sales of goods or rendering of services	9,959,146.69	23,746,923.08
Refund of taxes received	1,830,018.26	-
Cash received relating to other operating activities	319,893,036.24	392,557,057.48
Sub-total of cash inflows from operating activities	331,682,201.19	416,303,980.56
Cash paid for goods and services		
Cash paid to and on behalf of employees	198,268,353.73	175,096,805.93
Payments of taxes	3,581,028.61	2,998,873.33
Cash paid relating to other operating activities	354,711,378.39	335,261,609.11
Sub-total of cash outflows from operating activities	556,560,760.73	513,357,288.37
Net cash flows from operating activities	-224,878,559.54	-97,053,307.81

Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>II. Cash flows from investing activities:</b>		
Cash received from disposal of investments	21,444,469,956.33	1,907,476,522.38
Cash received from returns on investments	1,513,896,212.34	1,862,843,404.80
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	13,780,000.00	469,811.30
Net cash received from disposal of subsidiaries and other business units	641,000.00	–
Cash received relating to other investing activities	6,049,853,300.76	1,653,347,401.43
Sub-total of cash inflows from investing activities	29,022,640,469.43	5,424,137,139.91
Cash paid to acquire fixed assets, intangible assets and other long-term assets	42,002,289.61	106,802,588.22
Cash paid to acquire investments	33,887,100,000.00	3,235,316,500.00
Net cash paid to acquire subsidiaries and other business units	176,200,000.00	101,750,000.00
Cash paid relating to other investing activities	4,389,436,912.82	1,827,885,270.57
Sub-total of cash outflows from investing activities	38,494,739,202.43	5,271,754,358.79
Net cash flows from investing activities	-9,472,098,733.00	152,382,781.12



Items	The first three quarters of 2022 (January to September)	The first three quarters of 2021 (January to September)
<b>III. Cash flows from financing activities:</b>		
Cash received from capital contributions	13,963,893,388.88	–
Cash received from borrowings	1,600,000,000.00	1,750,392,561.76
Cash received from issue of bonds	14,997,633,333.34	15,994,758,880.37
Cash received relating to other financing activities	1,208,757,807.15	1,727,377,105.49
Sub-total of cash inflows from financing activities	31,770,284,529.37	19,472,528,547.62
Cash paid for repayments of debts	16,750,392,561.76	16,200,000,000.00
Cash paid for distribution of dividends, profits or interest payment	1,552,494,013.56	1,530,118,775.14
Cash paid relating to other financing activities	1,913,557,403.90	415,744,232.83
Sub-total of cash outflows from financing activities	20,216,443,979.22	18,145,863,007.97
Net cash flows from financing activities	11,553,840,550.15	1,326,665,539.65
<b>IV. Effect of foreign exchange rate changes on cash and cash equivalents</b>	-5,545,270.60	359,057.74
<b>V. Net increase in cash and cash equivalents</b>	1,851,317,987.01	1,382,354,070.70
Add: Balance of cash and cash equivalents at the beginning of the Reporting Period	4,716,238,699.67	3,989,558,641.83
<b>VI. Balance of cash and cash equivalents at the end of the Reporting Period</b>	6,567,556,686.68	5,371,912,712.53

Legal representative: ZHOU Jun                      The principal in charge of accounting: CHO Man  
Head of accounting department: SHEN Bo

**Particulars in relation to adjustments made to the financial statements as at the beginning of the year upon initial adoption of New Accounting Standard or interpretation of standards since 2022**

Applicable     Not applicable

It is hereby announced.

**The Board of Shanghai Pharmaceuticals Holding Co., Ltd.\***  
27 October 2022